Cipla has received final approval for its Abbreviated New Drug Application
(ANDA) for Valganciclovir Tablets 450mg from the United States Food and Drug Administration (US FDA).
Cipla's Valganciclovir Tablets 450mg is AB-rated generic therapeutic
equivalent version of Roche's Valcyte®. It is a deoxynucleoside analogue
cytomegalovirus (CMV) DNA polymerase inhibitor indicated for use in the
treatment of CMV retinitis in patients with acquired immunodeficiency
syndrome (AIDS) and prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk.